Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: High risk of viral reactivation even in a recipient with a vaccinated donor

Journal of Viral Hepatitis

Volumn 14, Issue 7, 2007, Pages 478-483

  Knoll A ^a   Boehm, S ^a   Hahn, J ^a   Holler, E ^a   Jilg, W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Allogeneic haematopoietic stem cell transplantation; Hepatitis B virus; Mutation; Reverse seroconversion; Vaccination

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CYCLOSPORIN A; DACLIZUMAB; DNA DIRECTED DNA POLYMERASE ALPHA; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MALE; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN MOTIF; SEROCONVERSION; VACCINATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REACTIVATION;

ADULT; ANTIVIRAL AGENTS; BLOOD DONORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 34250666293     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00830.x     Document Type: Article

References (22)

1. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994 93 : 230 239.
2. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996 2 : 1104 1108.
3. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005 41 : 1277 1282.
4. Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004 33 : 925 929.
5. Weinberger KM, Wiedenmann E, Böhm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 2000 85 : 75 82.
6. Weinberger KM, Kreuzpaintner EA, Hottenträger B, Neifer S, Jilg W. Mutations in the S-gene of hepatitis B virus (HBV) isolates from chronic carriers with anti-HBc as the only serological marker of HBV infection. In : Rizetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin : Edizioni Minerva Medica 1997 : 138 143.
7. Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002 30 : 189 194.
8. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998 66 : 616 619.
9. Goyama S, Kanda Y, Nannya Y et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002 43 : 2159 2163.
10. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005 79 : 616 619.
11. Hui CK, Sun J, Au WY et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005 42 : 813 819.
12. Parkman R, Weinberg KI. Immunological reconstitution following hematopoietic stem cell transplantation. In : Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden : Blackwell Science, 1999 : 704 711.
13. Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981 58 : 360 368.
14. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986 1 : 339 343.
15. Ilan Y, Nagler A, Adler R et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993 18 : 246 252.
16. Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000 26 : 633 638.
17. Ljungman P, Engelhard D, de la Camara R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005 35 : 737 746.
18. Locasciulli A, Testa M, Valsecchi MG et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997 90 : 3799 3805.
19. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990 336 : 325 329.
20. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998 27 : 254 263.
21. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 24 : 714 717.
22. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 24 : 711 713.